A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Inclusion Criteria: * Patients with GHomas confirmed by surgery * Patients who did not get biochemical remission: GH nadir after oral glucose tolerance test（OGTT）\>1.0ug/L or IGF-1 exceeds age matched normal range Exclusion Criteria: * Patients who were allergic to rosiglitazone * Patients with liver or kidney dysfunction, respiratory failure * Patients with heart failure * Patients with edema * Patients with severe hyperlipidemia * Patients with osteoporosis or a history of non traumatic fractures * Patients with pregnancy and lactation * Patients who had received radiation therapy within 3 years * Patients who had participated in other clinical trials within 3 months * Patients with other neoplastic diseases * Patients with mental and neurological disorders * Patients with other conditions which were believed not appropriate to take part in the clinical trial